Develops small molecule therapeutics that inhibit RNA-modifying proteins (RMPs) to target critical intracellular dependencies in multiple cancer types. This approach addresses the limitations of mutation-specific treatments by offering first-in-class and best-in-class candidates for patients with significant unmet medical needs.

Actio Biosciences develops targeted therapies for rare diseases by utilizing genetic insights to identify specific drug targets linked to single-gene disorders. This approach enhances understanding of disease mechanisms, enabling potential therapeutic applications for more common diseases with shared biological pathways.

Affinia Therapeutics develops adeno-associated virus (AAV) gene therapies using its proprietary Affinia Rationally-designed Therapies (ART) platform, which employs AI and structural modeling to enhance targeting and efficacy. The company focuses on providing transformative treatments for patients with severe diseases affecting the heart and nervous system.

Ajax Therapeutics develops next-generation, selective Type II JAK2 inhibitors to treat myeloproliferative neoplasms (MPNs). The company utilizes computational chemistry and structural biology to create best-in-class therapies that overcome limitations of existing Type I JAK2 inhibitors. Their lead candidate is currently in a Phase 1 clinical trial for myelofibrosis patients who have not responded sufficiently to current treatments.

Akouos develops gene‑therapy treatments for inherited hearing loss, using proprietary adeno‑associated virus vectors to deliver functional copies of defective genes directly to inner‑ear cells. Their platform combines precision, minimally invasive delivery with biomarker‑driven patient selection to restore or preserve auditory function, targeting otolaryngologists, audiologists, and pharmaceutical partners.

Aktis Oncology develops precision radiopharmaceuticals that utilize targeted alpha-emitting particles to treat solid tumors in cancers with limited treatment options. Their technology aims to enhance the efficacy of cancer therapies by delivering localized radiation directly to cancer cells, minimizing damage to surrounding healthy tissue.

Amagma Therapeutics employs a genetics-informed precision medicine approach to develop functional antibodies targeting immunological and inflammatory disorders. By utilizing a proprietary platform to identify and validate therapeutic targets with strong genetic rationale, the company aims to improve treatment options for diseases with limited existing therapies.

Arcus Biosciences develops combination therapies using differentiated small molecules and antibodies to enhance treatment efficacy for various cancers. The company focuses on optimizing biologic mechanisms to improve patient outcomes and accelerate the delivery of new cancer therapies through global clinical trials.

Artiva Biotherapeutics develops AlloNK, a non-genetically modified, cryopreserved natural killer NK cell therapy designed for the treatment of autoimmune diseases and non-Hodgkin lymphoma. The company addresses the limitations of current cell therapies by providing a broadly accessible treatment option that reduces the complexities and costs associated with patient-specific manufacturing.

Ashvattha Therapeutics develops hydroxyl dendrimer-based nanomedicines that selectively target activated cells in inflamed tissues, addressing unmet medical needs in ophthalmology, neurology, and inflammatory diseases. This precision approach enhances treatment efficacy by ensuring that therapeutics are delivered specifically to areas of inflammation, minimizing off-target effects.

Attovia is developing a pipeline of biotherapeutics for immune-mediated diseases and oncology using its proprietary ATTOBODY platform, which enables the creation of bispecific and multispecific antibodies with picomolar affinity and enhanced tissue penetration. This technology addresses the lack of effective treatment options for patients by providing first-in-class mechanisms of action that improve therapeutic efficacy.

Basecamp Bio develops cell and gene therapies using proprietary technologies such as gene editing, RNA engineering, and viral delivery systems to create effective treatments for various diseases. The company addresses the need for efficient manufacturing and development processes in the regenerative medicine sector, enabling faster access to life-saving therapies.

Cellares develops the Cell Shuttle™, a modular, cGMP platform that automates cell therapy manufacturing using a closed, single-use cartridge system. This technology increases productivity by tenfold and reduces costs by up to 50% compared to conventional contract development and manufacturing organizations (CDMOs), while also minimizing process failure rates.

Centessa Pharmaceuticals develops potential transformative medicines for patients with sleep-wake, neurological, neurodegenerative, and neuropsychiatric disorders. The company is advancing its Orexin Receptor 2 Agonist Program as a key therapeutic focus. They leverage an asset-centric approach to pursue novel treatments in these complex disease areas.

Codiak BioSciences Inc is developing exosome-based therapeutics using its engEx Platform to create engineered exosomes for the treatment of diseases with high unmet medical needs, including oncology and neuromuscular disorders. The company aims to provide targeted delivery of therapeutic agents, improving treatment efficacy and patient outcomes in complex disease areas.

Denali Therapeutics uses its proprietary TransportVehicle™ platform to deliver enzyme‑based biologics across physiological barriers, enabling treatment of neurodegenerative diseases and lysosomal storage disorders throughout the body, including the brain. The company’s pipeline includes multiple investigational candidates and the FDA‑approved therapy AVLAYAH™ for Hunter syndrome, demonstrating its ability to create disease‑modifying treatments for serious unmet medical needs.

Dewpoint Therapeutics is developing a drug platform that targets biomolecular condensates, which are implicated in the dysregulation of complex diseases. By integrating AI with advanced experimental technologies, the company aims to create therapies for conditions previously considered undruggable.

Eikon Therapeutics develops a proprietary single-molecule tracking platform that utilizes super-resolution microscopy to measure protein dynamics in living cells, enabling detailed analysis of molecular interactions. This technology addresses the challenge of understanding protein behavior, which is critical for identifying new drug targets and advancing therapeutic development for serious diseases.

Epikast provides biopharma and healthcare companies with a peer‑to‑peer engagement platform that combines medically trained talent and AI‑driven analytics to connect with physicians, other healthcare providers, and patients across the US and Europe. The service reduces operational costs by 40% or more, scales outreach through multi‑channel virtual, digital, and in‑person interactions, and delivers real‑time insights to refine messaging and strategy.

Freenome provides a blood‑based early cancer detection platform that uses multiomics profiling—integrating genomics, epigenomics, proteomics, and metabolomics—with AI‑driven analysis to identify cancer at its most treatable stages. The minimally invasive test is designed for routine screening across multiple cancer types and is validated through ongoing clinical programs for use by healthcare providers.

Gossamer Bio is a clinical‑stage biopharma developing seralutinib, an inhaled small‑molecule inhibitor of PDGFRα/β, CSF1R, and c‑KIT, for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH‑ILD). The drug is delivered via a dry‑powder inhaler to target lung tissue directly, aiming to reduce vascular inflammation, proliferation, and fibrosis while minimizing systemic side effects. Seralutinib is currently in Phase 3 trials following promising Phase 2 results.

Intellia Therapeutics develops in vivo CRISPR‑Cas9 gene‑editing medicines that directly correct disease‑causing mutations in patients with severe monogenic disorders. Its platform integrates guide‑RNA design, lipid nanoparticle/AAV delivery, safety screening, and GMP manufacturing to advance candidates from target discovery through clinical trials, aiming for single‑dose curative treatments.

Kronos Bio develops therapies that target dysregulated transcription factors within their transcriptional regulatory networks to treat hard-to-reach cancers and autoimmune diseases. Their pipeline includes molecules like Istisociclib, a CDK9 inhibitor for MYC-dependent tumors, and KB-9558, which targets the KAT domain of p300 in multiple myeloma and HPV-driven tumors.

Kumquat Biosciences provides a cloud‑based platform that combines high‑throughput phenotypic screening with machine‑learning analysis to speed up target identification and lead optimization. The service automates assay design, image capture, and data processing, delivering dose‑response curves, hit‑validation metrics, and predictive models through a secure web portal. It integrates with existing lab automation and LIMS systems, enabling early‑stage biotech, academic, and pharma teams to reduce experimental cycles from weeks to days.